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Abstract
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are being looked into as a possible solution due to the polypeptide Amylin. An explanation for the
connection between Amylin and type 2 diabetes is given, by explaining each separately and then
connecting the amyloid fibril formation to type 2 diabetes. The information provided was collected
through an extensive literature review.
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Introduction to Type 2 Diabetes:

Diabetes is a chronic disease that affects millions around the world, and is also the
leading cause of kidney failure, nontraumatic lower limb amputation, and new cases of blindness
among adults. Overall, it is the seventh leading cause of death and a major cause of heart disease
and stroke. A disease that affects more than twenty five million people of all ages and 8.3% of
the American population is one that needs to be urgently addressed from all angles possible.
(National Diabetes Clearinghouse, 2011). Not only is diabetes a leading cause or underlying
factor in many other life threatening illnesses, but it also is a very costly disease. Statistics
released in 2007 by the National Diabetes Association estimated that the total cost of diagnosed
diabetes in the United States was $174 billion, with $116 billion being spent on direct medical
costs, and $58 billion being spent on indirect costs such as disability, work loss, or premature
mortality (American Diabetes Association, 2011 ).
The media can drastically shape the public's opinion on a disease that affects so many
people because people want to find out about their disease themselves and not just through their
doctors. This means that they obtain their inf01mation on the disease from the large number of
advertisements and articles published in the media. The public's perception of diabetes is a
generally uneducated view of the disease in which people may look at it and assume the persons
suffering brought it upon themselves or that it is not a serious condition. A common public
misconception, which is perpetuated through the media, is that diabetes is a disease caused by
overeating and lack of exercise, because the media puts so much focus on lifestyle and obesity
being causative factors. The media gives double the amount of coverage to the behavioral risks
of diabetes than to any other contributing factors, according to Sarah Gollust, an assistant
professor at University of Minnesota School of Public Health (Lynch, 2012). Another public
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misconception is that diabetes is not a serious condition and just requires the patients to be
subject to finger pricks and medication for the rest of their lives.
Diabetes is divided into type 1 and type 2 diabetes mellitus based on several factors. The
main distinguishing factor is whether or not the person is insulin dependent or if an insulin
resistance is developed over time. While type I and type 2 diabetes can occur at any point in life,
type 1 diabetes is usually characterized by an onset at an early age or in adolescence. The exact
cause of type 1 diabetes is unknown, but it is thought to be beta cell destruction that leads to the
pancreas producing no insulin for the body (Eckman, 2011).
It is a fatal issue in type I diabetes if the body does not produce insulin, because insulin is

a hormone that is needed to convert glucose, more commonly known as sugar, into energy for
the cells of the body to use to perform vital functions. Without insulin, the body enters a state of
hyperglycemia, which is a high blood glucose level, because all of the glucose taken in by the
body remains in the bloodstream without insulin to help the sugar enter the body's cells. This is
the reason all type I diabetics are considered insulin-dependent because their bodies do not
produce the insulin necessary for survival, so people with type I diabetes must supplement the
insulin in their systems, in most cases through an injection or pump.
Type I diabetes is a rather straightforward condition where the body does not produce insulin,
and, therefore, it must be supplemented for survival, but type 2 diabetes is much more complex
because there are multiple ways in which it develops within the body and several different routes
of treatment. Of the 8.3% of the population that has diabetes (over 25 million individuals), 9095% of those individuals are diagnosed with type 2 diabetes. While these numbers in themselves
are staggering, it is estimated that of these 25 million people, 7 million people me undiagnosed,
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and on top of this number, 79 million people have been diagnosed with a condition called
prediabetes (American Diabetes Association, 20 II).
Prediabetes is the classification of having a slightly elevated glucose level from I 00-126
mg/dL, which is higher than the recommended 80-IOOmg/dL, but is not high enough to be
considered type 2, which is above 126mg/dL, according to the American Diabetes Association
(20 12). Prediabetes is becoming an increasingly prevalent diagnosis from doctors worldwide as
it is becoming more necessary to diagnose prediabetes since treatment of this condition could
lead to the prevention of a more serious condition. According to the Mayo Clinic, " ... without
intervention, prediabetes is likely to become type 2 diabetes in 10 years or less" (2012). The goal
in diagnosing prediabetes is that an individual will take the correct lifestyle modification steps to
bring one's blood sugar levels back to normal instead of allowing the long-term devastation that
type 2 diabetes can have on the body to develop.
Type 2 diabetes differs in presentation from type I in that it typically has a later onset in
life than type I, but in recent years, the drastic increase in childhood obesity has also led to
higher rates of prediabetes and type 2 diabetes in people under the age of twenty. As per the
American Diabetes Association's statistics released in 2011, 215,000 people under the age of
twenty have Type II diabetes, meaning that one in every four hundred people in this age group
has diabetes. Type 2 diabetes can be asymptomatic for a very long time, which is why the
numbers are so high for undiagnosed diabetes. As mentioned previously, type 2 diabetes can
develop for many reasons showing a prevalence in people of certain ethnicities, in people who
are obese, and in people with a strong family history of the disease. All of these characteristics
are risk factors that raise an individual's chances of developing this life-altering disease. Once
the American Diabetes Association accounted for the adjustment in population age differences,
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the latest numbers from 2007-2009 of people diagnosed with diabetes show that the highest
ethnic group over the age of twenty was non-Hispanic African Americans at 12.6%, followed
closely by Hispanics at 11.8% (20 12).
Diagnosis of type 2 diabetes usually occurs at a routine physical when blood work is
taken and the fasting plasma glucose levels come back elevated. A fasting plasma glucose is the
most common test done in a blood work up when checking blood sugar levels, but, to be
diagnosed with type 2 diabetes, the test must be done after a twelve hour fast on two separate
days, with numbers coming back above or equal to 126mg/dl, when normal munbers are
considered to be 80-1 OOmg/dl. Standard lab testing will allow for the nmmal values to be met if
the fasting is done correctly, but it is very difficult to diagnose a person with diabetes from one
set of values due to many outside factors that could influence test values the day blood is drawn.
For this reason, it takes a minimum of two tests resulting in numbers that suggest high blood
glucose to diagnose an individual with diabetes (Kaput eta!. 2007).
If a person develops type 2 diabetes it can be as a result of many risk factors, including
obesity or a strong family history. There is thought to be a genetic link if family members have a
history of the condition, and obesity, coupled with a lack of exercise can lead to type 2 diabetes
because it can cause insulin resistance. With type 2 diabetes, pathogenesis can occur in the form
of two defects. Unlike type 1 diabetics, type 2 diabetics produce insulin, but the pancreas either
does not produce enough insulin or the insulin cannot be used by the body as it is supposed to be
used. If enough insulin is not produced or it cannot be taken up into the cells as it is supposed to
be, glucose builds up in the bloodstream (Kaku, 201 0). With a build up of glucose in the
bloodstream due to the resistance of cell uptake of glucose, multiple body systems can be
harmed, and cells cannot function properly because they are not receiving the energy they need
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from the glucose. Insulin is always released in small amounts by the pancreas in order to
regulate the amount of glucose being delivered to cells for energy, and when the amount of
glucose in the system rises, the pancreas is triggered to release more insulin to compensate and
push the increased glucose into the cells, causing the amount in the blood stream to drop. When
the blood glucose levels begin to get too low, a condition known as hypoglycemia, the body
begins breaking down glycogen to create more glucose, as well as signaling the body to eat in
order to gain more glucose from the carbohydrates in a meal. In a type 2 diabetic, this
homeostatic system is not kept in balance because either the pancreas cannot produce enough
insulin to keep up with the demand or the body's cells develop an insulin resistance that strictly
restrict or discontinue the uptake of glucose by the cells. Both deficiencies lead to a high blood
glucose level above 126 mg/dL (DeFronzo 2004).
Just as diabetes is caused by pathophysiology within the body through issues with the
pancreas creating insulin or the liver releasing glucose, there is a pathogenesis behind the
complications for which diabetes is most commonly known, such as the degradation of
endothelial and mesangial cells (Browulee, 2004). The reasons these cells are so vulnerable to
high blood glucose is because they are not able to control their intake of blood glucose like other
cells in the body, which are able to adjust to the high levels of blood glucose and develop a
resistance to allowing more blood glucose to enter cells by closing channels or transporting in
less. Cells of the retina or of the nephron lack this innate ability to do adjust and resist and
therefore are damaged by hyperglycemia. These repeated acute changes in the body's cellular
metabolism lead to both micro and macrovascular tissue damage. Over a prolonged period of
time, the cumulative changes summate and the damage becomes irreversible. Morever, when
independent accelerating factors that often coincide with diabetes, such as hypertension or
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hyperlipidemia, occur, these complications become increasingly significant. This degenerative
path that begins with a simple elevated blood glucose level can lead to complications, such as
retinopathy resulting in blindness or nephropathy resulting ultimately in kidney failure
(Brownlee, 2004).

Not only is it important to treat such a chronic disease to prevent the

immediate harm to the body, but also to minimize the serious complications that type 2 diabetes
can cause if not treated.
Treatment plans for type 2 diabetes can vaty greatly, beginning with lifestyle
modification and including medication, as well as insulin for the more extreme cases where there
is an insulin deficiency. With lifestyle modification, type 2 diabetes can be reversed, and blood
glucose levels restored to normal values, which are 80-100 mg/dL. Obesity is a big contributor to
type 2 diabetes, and it is one of the biggest risk factors. Lifestyle modification will often include
eating a healthier diet and exercising more often. The most important macronutrient to a
diabetic's diet is carbohydrate when it comes to maintaining blood glucose levels. There are
simple carbohydrates, which will raise blood glucose quickly, and there are complex
carbohydrates, which will provide a slower rise in blood glucose but will keep the levels more
even. Simple carbohydrates, which are necessmy in a hypoglycemic state and can be utilized
faster due to being digested faster include foods such as juice, candy, cookies or tablets of pure
glucose. Complex carbohydrates, which should be consumed during meals to provide a steady
level of blood sugar, include whole grains, starchy vegetables, and pasta. When modifYing one's
lifestyle in order to bring about a positive change in blood glucose levels, the goal in obese or
overweight individuals is weight loss because weight loss can lead to increased glucose uptake in
cells and decreased resistance to insulin. In order to improve these odds, a diet can be modified
to decrease sugar, fat, and salt intake and to increase whole grain, legume, and fiber intake. The
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American Diabetes Association suggests a meal management method called the Plate method,
where a plate is cut in half. On one half of the plate, there are vegetables. The other half is then
cut in half again, with one half being filled with potatoes, rice, or pasta, and the other half being
filled with meat, poultry, and fish. Type 2 diabetics can focus on a food's glycemic index, a
measure of how a carbohydrate-containing food will raise blood sugar, when choosing what to
eat in each meal (American Diabetes Association, 2012). A glycemic index is based off of a
reference food being glucose or white bread, and foods with a high index can be balanced with
foods with a low index to create a healthy balance. Examples of foods with a high glycemic
index include white bread, bagels, pretzels, and melons all of which will raise blood glucose
quickly. Foods with a low glycemic index include oatmeal, most fruits, and non-starchy
vegetables. Paying close attention to the glycemic index of foods in combination with
carbohydrate counting is a great way for type 2 diabetics to try and control their blood glucose
based on their diet. Not only does lifestyle modification ensure that a diabetic is making better
food choices, but it also includes increasing the amount of physical activity received.
In December of 2010 the American College of Sports Medicine and the American
Diabetes Association released a joint statement regarding exercise and type 2 diabetes. This
atiicle makes the bold and clear statement that "it is now well established that participation in
regular physical activity improves blood glucose control and can prevent or delay type 2
diabetes, along with positively affecting lipids, blood pressure, cardiovascular events, mortality,
and quality of life" (Colberg et al. 2010). The combination of physical activity and modest
weight loss can decrease the risk of this cln·onic disease in high risk populations by 58%, and can
be accomplished by both aerobic and resistance training. It is thought that the preferred type of
exercise for a type 2 diabetic is to exercise at 50-70% of a maximal heati rate for 40-60 minutes
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about five days a week. The combination of resistance training and aerobic training is best suited
for blood glucose control because, " any increase in muscle mass that may result from resistance
training could contribute to BG uptake without altering the muscle's intrinsic capacity to respond
to insulin, whereas aerobic exercise enhances its uptake via a greater insulin action, independent
of changes in muscle mass or aerobic capacity" (Colberg eta!. 2010). This joint statement also
went on to discuss the acute effects of exercise on glucose levels, including increased glucose
uptake by muscles increased glucose transport, and increased glucose metabolism, all of which
are seen during exercise. Not only is evidence given for these statements, but the same studies
provide evidence that the chronic effects of exercise increase insulin binding activity at insulin
receptors, cells become increasingly permeable to glucose, and increase the peripheral glucose
uptake is also increased. While lifestyle modification through healthy dietary and exercise habits
is the first line of defense against those diagnosed with type 2 diabetes, it is not always
successful or an effective enough treatment to control the diabetes. In this case, medication can
be used to try and control blood glucose levels.
Oral medication is the first line of defense when it comes to medically controlling type 2
diabetes. There are two

m~or

classes of oral medications that are seen most commonly and

work on different parts of the pathophysiological pathway. The first type discussed is also the
oldest type of medication called Sulfonylureas. The action of this type of medication stimulates
the pancreas to release more insulin, and its advantage is speed of onset. Some examples include
Glipizide and Glimepiride (MayoClinic, 20 II). The other class of medication, which is by far the
most commonly used oral medication for type 2 diabetes, is the Biguanides, which include the
medication Metformin. Metformin is the first line of defense in oral medication for type 2
diabetics due to its affordability, drug safety, and efficacy. The mechanism of action of a
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Biguanide is to inhibit the release of glucose from the liver and to increase cell's sensitivity to
insulin. As far as drug safety is concerned Metformin's largest counter-indication relates to type
2 diabetics with poor renal or liver function. Depending on how severe the type 2 diabetes has
become in an individual, nephropathy can be caused by type 2 diabetes, and, therefore serum
creatinine levels must be checked thoroughly before prescribing Metformin (MayoClinic, 2011 ).
In cases where lifestyle modification and oral medication is not enough to control the
diabetes, insulin may be prescribed as part of a treatment regimen for a type 2 diabetic. The
insulin acts the same way in type 1 and type 2 diabetes, where it is replacing what the body
cannot naturally make itself. In a type 2 diabetic, the body may still be producing insulin, but
even through oral medication, it may not be producing enough to keep up with the demands of
the cells in the body, so injections of the hormone must be made subcutaneously to provide the
body with what it cannot produce on its own. Lifestyle modification, oral medications, and
insulin are all treatment options available for type 2 diabetics, and they generally proceed in such
an order. If the diabetes is caught early enough, then the hope is that exercise and healthy eating
can be a sufficient treatment to stimulate positive bodily effects allowing more glucose
utilization and insulin production. Regardless of the ability for these goals to be reached through
a change in habits or tlu-ough medication, there is no cure for diabetes. Once diabetes is
diagnosed, a cure does not exist that can make one free of the chronic illness (Mayo Clinic 2012).
Diabetes can be reversed if it is well-maintained, but it is a constant battle that will forever be
fought within one's body.
The future options for treatment of type 2 diabetes are endless and are being approached
from as many innovative angles as possible. The current treatment for the disease is symptom
management - future treatments will be looking for a cure or at least for a way to manage this
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disease, whether it be through genetics, new medications, or a biochemical approach. New
advances are being made evety day in the hopes of making this disease an illness of the past,
because, at the rate at which it is growing, the diabetes epidemic is something that needs to be
stopped in some way. One very promising lead seems to be through the investigation of a
particular polypeptide, Amylin, and it's potential effects on the seventh most deadly issue faced
worldwide.
Introduction to Amylin:

Amino acids are the building blocks for proteins that form the primary structure by the
linkage of peptide bonds. Every amino acid contains an amino group, as well as a carboxyl
group, and an R group, which is a carbon chain that uniquely identifies each amino acid. The
chemical properties of the R group are what classifY an amino acid. In the peptide bonds that
connect amino acids, the amino group of one bonds to the carboxyl group of another, forming a
peptide. A polypeptide is a long chain of amino acids linked together. The formation of a protein
is derived from a single or multiple polypeptides linked together to fmm tertiary and quaternary
structures. The primary structure is the order in which the amino acids are linked together by
peptide bonds, and the secondary structure is due to the hydrogen bonding between the oxygen
atom of one amino acid and the amine hydrogen of another. The tertiary struch1re is derived from
the three dimensional structure formed when the secondary structure folds on itself, and the
quaternary structure involves several polypeptides bonding together.
The peptide in question with regards to type 2 diabetes is amylin, or Islet Amyloid
Polypeptide (IAPP). IAPP is a 37 residue polypeptide hormone that is secreted in conjunction
with insulin from the pancreatic beta-cells in a 100:1 ratio (Brender et a!. 20ll). lAPP is
expressed on gene 12 by one single gene copy on the short mm of the chromosome (Westermark
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eta!. 2011).

In type 2 diabetes. amylin misfolds and causes fibril formation. Usually, amyloid

fibrils are formed by soluble proteins, which assemble to form insoluble fibers that are resistant
to degradation. In a healthy individual, amylin is cosecreted with insulin fi·om the beta cells and
is then excreted via the kidneys. The occurrence of islet amyloid fibril formation is less than
15% in non-diabetic patients, but is present in over 90% of diabetic subjects (Jaikaran, 2001).
Amyloid is only seen in type 2 diabetics, because, in type 1 diabetics, the lAPP source is
removed due to the destruction of the beta cells. Because insulin and lAPP are cosecreted, an
increased level of human Islet Amyloid Polypeptide (hiAPP) which occurs in a state of insulin
resistance, where insulin secretion increases to compensate can initiate the fibril formation.
When lAPP is stored in the secretory granules of the beta-cells at about one to four millimolar
concentration, which is about a thousand times the amount that is necessary to form amyloid
fibrils.
There are certain characteristics of amylin, as well as amino acid residues in the 37 amino acid
peptide, that are very important in the process of fibrillar formation of amy lin. One characteristic
lAPP shares with other peptides in the calcitonin family is the inclusion of a disulfide bridge
between residues 2 and 7 and an amidated COOH terminus, which are modifications made after
translation that are important to the biological function of these peptides in the calcitonin family
(Westermark eta!. 2011). In this same article, "Islet Amyloid Polypeptide, Islet Amyloid, and
Diabetes Mellitus", Westermark and colleagues described the tertiary structure ofiAPP;
"Both CD and NMR studies have shown that the peptide forms an at least transient
amphipathic helix in the NH2-terrninal region, except for the very NH2- terminal part,
which forms a rigid ring structure, resulting from the disulfide bridge between residues 2
and 7. In solution, the helix spans residues 5-23. The COOH-terminal part of the
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molecule is unstructured. The helical part is believed to be important in receptor binding
and may also be deeply involved in the pathological transformation to amyloid fibrils"
(2011).
Proline substitutions in the amino acid residue region on lAPP from 20-29 are involved in
rat islet amyloid polypeptide (hiAPP) and rats do not develop diabetes (Jaikaran, 2001). This
indicates the importance of this region in forming amyloid.

There is also a second

amy1oidogenic region, hiAPP 30-37 which when placed in a medium formed fibrils, as well as a
third region from 8-20 that is under investigation. These three proline residues are seen in rat
lAPP, but not in human lAPP and the presence of these proline residues is thought to prevent
hiAPP from becoming amyloidogenic. The aggregation of hlAPP is completed within a few
hours depending on other factors, such as the presence of lipids, and this aggregation is
significantly faster than those of most other amyloidogenic peptides. According to Brender and
colleagues, "Amyloids fmm through a nucleation-dependent process leading to characteristic
sigmoidal type kinetics; in which amyloid formation is minimal (the lag-phase) until a critical
concentration of nuclei is reached, at which point amyloid growth proceeds explosively" (20 11 ).
During the formation of stable fibrils, nucleation must occur, and the nucleus is an oligomeric
hiAPP species that can serve as the template for the fibrillar version. Initially, an alpha-helical
structure is adopted before transforming into a beta-sheet structure, and it is thought that the
oligomers can exhibit an alpha-helical structure. During the formation of the amyloid fibrils, a
conformational change takes place, in which the structure changes from a random coil to a
mixture of alpha-helical and beta-sheet structure (Khemtemourian et a!. 2008).
The cardinal finding in type 2 diabetics as far as pathogenesis in the islet cells is the
fmding of these amyloid fibrils. Characteristics of the amyloid fibrils found in these islets
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include them being unbranched, thin, and of an indefinite length. The monomers are ananged in
a beta-sheet perpendicular to the fibril axis. The nucleation process of amyloid formation can be
broken down into three phases, the first of which is called the lag phase. Here, the nucleation of
these monomeric peptides occms. The second phase is known as the elongation phase, where the
critical amount of nucleation can occm, and then in quick fashion propagates the formation of
the fibril. As discussed above, once the nucleation occms, the formation of the fibrils is a very
quick process in reference to lAPP, whereas other amyloid fibril formation is typically done at a
slower rate. Once the elongation phase has completed, the third phase in in vitro systems is the
plateau stage, where the fibril has reached a constant mass and is considered to be in its steady
state (Westermark et al. 2011). The interesting revelation about amyloid formation is that the
matme fiber does not have any significant cell toxicity. While the buildup of amyloid fibrils in
the islet cells is an indicator of type 2 diabetes, as well as other types of amyloid fibril build up in
other organ systems being large enough masses to cause severe disease, the mature fibrils
themselves are relatively inactive. What seems to be causing the cytotoxicity is the intermediates
from lAPP to amyloid fibrils, namely the oligomer transition states. "Subsequent reports have
underlined that it is small, oligomeric lAPP aggregates and not fibrils that constitute the toxic
species," according to Westermark and associates in his article published by the American
Physiological Society in 2011.
Oligomers are ill-defined and hard to study because they can only be studied after they
have formed, and they have been exclusively studied in vitro, with the suggestion that they are
inserted into cell membranes. It has been suggested that the cytotoxicity arises from the damage
these oligomers cause, whether it be through the fmmation of pores in the membrane or through
nonspecific membrane disruption. The methods by which these oligomers cause cytotoxicity are
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still topics of investigation. In Westennark's article, an explanation for the cytotoxicity 1s
explained as the following process,
"In a proposed model on lAPP cytotoxicity, based on fmdings when lAPP was absorbed
onto or inserted into a lipid membrane, the 19 NH2-tenninal amino acid residues are
inserted in the membrane. Insertion in this way leaves the amyloidogenic segment of
residues 20 -29 free to aggregate, and fibril growth will force the membrane to rupture"
(2011).
Now the question is tumed away from the issue of mature fibril formation and is becoming more
of a question of the oligomeric intermediates associated with beta cell death. The key to
connecting the role of amyloid fibril fmmation and type 2 diabetes lies in understanding the
mechanism behind the cytotoxicity of the intermediates. If the mechanism of cytotoxicity can be
determined, whether it be tlu·ough damaging the membrane or some other form, then it gives a
stmiing point to detennine how to prevent the damage causing the cell toxicity. Research shows
that the aggregation of lAPP oligomers plays a crucial role in the progression of beta cell death
in transplanted islet cells, leading to support for a similar mechanism in type 2 diabetes. Such
research results that could lead to an explanation of cell toxicity in the beta cells and could also
open doors for the possibilities of new treatments for type 2 diabetes.
Connecting Amylin and Type 2 Diabetes

There are many different factors that allow the assumption to be made that the fibrillar
transformation of the 37 amino acid residue, amy lin, into a mature amyloid fibril, which occurs
in a process producing many oligomeric intermediates, can be linked at the biochemical level as
pmi of the cause of beta-cell death that can lead to type 2 diabetes. Proof of such a statement has
been shown through amyloid formation in transplanted pancreatic islet cells. Experimental islet
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cell transplantation was done, in which human islet cells, once they became available, were made
diabetic by injection and were then used in studies testing the effects of hyperglycemia on human
beta cell function. The following quote describes the importance of the human islet grafts
becoming available and their effect on the research of amyloid fibrils in diabetes.
"Keeping in mind the difference in the IAPP amino acid sequence that prevents amyloid
formation in rodent islets, the availability of human islet specimens in an in vivo setting of this
kind has paved the way for experimental studies of the presence of fibrillogenic IAPP and
accompanying amyloid formation in human islets" (Westermark eta!. 2011 ).
With the human islets it was found that the alpha cells remained intact, while the beta
cells decreased in number and amyloid fibrils were found densely packed intracellularly with
their plasma IAPP levels being increased more than five times that of the baseline value. This
data in human islets differed from rat islets, which showed only very sparse amyloid fibrillar
formation, but that was to be expected due to the differences in the amy lin sequence that prevent
fibril formation in the rodent IAPP amino acid sequence.

The results of such studies of

transplanting the pancreatic islet cells proved a firm connection between amyloid fibrils and the
destmction of beta cells that can lead to type 2 diabetes:
"Furthermore, recent studies of human IAPP transgenic islets or control islets grafted into
streptozotocin-diabetic mice showed that hyperglycemia recurred only in mice that had
received transgenic islets. Amyloid deposition occurred prior to the recurrence of hyperglycemia, and was accompanied by increased rates of beta-cell apoptosis and decreased
beta-cell replication. The accumulation of amyloid correlated with the loss of beta-cells
"(Weste1mark eta!. 2011).
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Type 2 diabetes is "characterized by a slowly progressive degeneration of islet beta-cells,
resulting in a fall of insulin secretion and decreased insulin action on peripheral tissues"
(Miklossy et al, 2010). This same study, published by Miklossy and colleagues in 2010,
demonstrates the deposition of amyloid material as a major pathological factor in type 2 diabetes.
The facts indicate that amyloid deposits are seen in over 95% of type 2 diabetics and that the
severity of the disease positively correlates with the extent of islet amyloid deposits.

The

presence of clinically silent and moderate amyloid deposits can possibly correspond with early,
preclinical stages of type 2 diabetes. The correlation between amyloid deposits and type 2
diabetes provides a window of opportunity for an early detection of the disease through this postmortem research.
Beta cell death is one of the causes behind type 2 diabetes because, when the beta cells
die, insulin is not being released to keep blood glucose levels within the normal range of 80-100
mg/dL. Without the beta cells from the pancreas to synthesize and release insulin, hyperglycemia
will occur. As previously stated, lAPP fibrils are located at the cellular membrane of the Islet of
Langerhans, and the presence of these fibrils leads to alterations in the membrane morphology.
One hypothesis states that the membrane could be the target of the cytotoxicity of these fibrils,
causing the death of the beta cells that produce insulin. Type 2 diabetes is associated with
increased insulin resistance, and, since lAPP is coproduced and cosecreted with insulin, an
increase in the level of lAPP in human cells could initiate lAPP fibril formation. This would
produce an altered ratio of insulin to lAPP, which is observed in diabetic patients and could lead
to a decrease in the inhibitory effect of insulin on lAPP amyloid fibril formation. In a healthy
individual, amyloid is not observed, in part because the fibril formation is typically inhibited by
insulin. Insulin should be produced in 50-100 molar excess of lAPP, and this is a sufficient
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amount for it to suppress amyloid formation in healthy individuals (Hebda and Miranker, 2009).
In an article, "Atomic Structures of IAPP Fusions Suggest a Mechanism for Fibrillation and the
Role of Insulin in the Process", published in 2009, offers evidence through a fusion crystal
structure that suggests, " Insulin binds to IAPP in the same way that an IAPP monomer binds to
the second monomer of the dimer ... These molecules rotate to bury more smface area than in the
IAPP dimer structme, suggesting the possibility of a tighter interaction between IAPP and insulin
than between two IAPP molecules" (Wiltzius eta!.). One hypothesis is that an increase in lAPPmembrane interactions could lead to the development of type 2 diabetes (Khemtemourian, 2008).
One of the most widely investigated hypotheses that approaches the connection between
type 2 diabetes and IAPP suggests that the damage caused by its interaction with the cell's
membranes. Observations have shown that phospholipid membranes promote the aggregation of
human IAPP, and that in the presence of phospholipids there is a reduction in lag time, causing
fibril formation to occm earlier. Cell membranes may accelerate hiAPP fibril formation by
enhancing nucleation, and formation of these fibrils is markedly accelerated in the presence of
membranes containing negatively charged lipids. The time difference is substantial, with fibril
formation occurring within a few minutes in the presence of these negatively charged
membranes as opposed to within a few hours in the absence of such membranes
(Khemtemourian, 2008). It has become clear that the cytotoxicity of these fibrils is derived from
their inte1mediate states rather than from their matme fibrils (Hebda and Miranker, 2009). The
review article published by Khemtemourian and colleagues discussed studies performed to
determine the conformation of hiAPP that interacts with model membranes. The model
membranes were composed of a neutral phospholipid and a negatively charged phospholipid and
when hiAPP, when incubated with the model membrane for forty minutes, made changes to the
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beta sheet conformation, which is the characteristic of fibril formation as already discussed.
Using microscopy techniques, it was fotmd that hiAPP morphology was connected to channellike behavior indicating that the oligomeric (fewer than 5 monomers linked together) hiAPP
pores could become part of the membrane, changing the banier properties of such membranes.
This experimental diabetes research took a step further to look at the mechanism of cytotoxicity,
stating that the membrane is the target of the cytotoxic lAPP leading to the death of the insulinproducing beta cells. The mature hiAPP fibrils were found to be less cytotoxic and did not cause
the membrane damage that the oligomeric form of hiAPP did. This review by Khemtemourian
discusses the view that "lAPP-induced membrane damage, and concomitant beta-cell death, is
caused by cytotoxic hiAPP oligomers" (2008). Surprisingly, once the oligomers matured into
fibrils the pores formed in the membrane disappear and damage decreases. Yet the oligomeric
form of hiAPP can carry out a general destabilizing effect when applied outside or inside a cell.
If these oligomers can reach the endoplasmic reticulum or mitochondria within a cell
endoplasmic reticulum stress occurs leading to the apoptosis of the beta cells (Khemtemourian et
al, 2008). It is able to be seen that the mature amyloid fibrils would be less destructive because
they are stable, proteinaceous structures. In Hebda and Miranker's study of type 2 diabetes and
the role that catalysis and toxicity of amyloid plays on the lipid bilayer, the statistic was
presented that over 90% of type 2 diabetics have evidence of amyloid deposition, but the
question arises about the other l 0%. The remaining percentage of patients are what led to the
theory that the intermediates of amy lin may play a role, because a protein can be ascribed to a
specific disease as a causal factor, but it does not have to be the mature fibrillar form that causes
disease all the time. Similar studies were done using lAPP-membrane interactions with rodents
and mouse transgenic lines of hiAPP in five different studies conducted by three different
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groups. The rodents developed a loss of up to 60% of their beta cells correlating with
hyperglycemia and amyloid deposition. The proof that intermediates of amyloid play a more
cytotoxic role in type 2 diabetes is that in rodent studies done using the introduction of a single
amyloidogenic peptide into nontransgenic rodent models, an increase was observed in beta-cell
death without the subsequent amyloid depositions. This provides evidence that not plaques of
lAPP fibrils depositions but more likely the intermediates that form such plaques contribute to
the origin of beta cell toxicity (Hebda and Miranker, 2009). This study, as well as
Khemtemourian's, points to the possibility of endoplasmic reticulum stress as a possible origin
for amyloid induced toxicity. The fact remains that a defmite answer is yet to be discovered and,
"For lAPP, toxicity could be the result of membrane disruption, at any point along the secretory
pathway, from ER to Golgi, granule, or plasma membrane" (Hebda and Miranker, 2009).
Through newer technologies that are constantly evolving and being used to test
hypotheses such as the ones suggested above, advancements have been made to prove the lAPPmembrane interaction hypothesis. A study published results in the Journal of Molecular Biology
in 2012, relying on fluorescence microscopy leakage assays to reveal the membranepermeabilizing effect of lAPP. In order to detect the permeabilization of vesicles that should
occur during aggregation and fibril formation, lAPP was labeled at the C-terrninus with a lysine
residue, and when fluorescence microscopy was used, pure lAPP was seen in the interface of the
lipid vesicles five minutes after it's addition. Within the next few minutes lAPP amounts
increased leading to permeabilization and leakage of the membrane. Even after forty minutes of
aggregation, lAPP aggregation of vesicle-like shape was still detectable, suggesting that some of
the lAPP was incorporated into the growing peptide aggregates (Seeliger et al. 2012). The final
conclusions of this study led to the postulation of a multiple step mechanism where the insertion
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of the positively charged N tenninus ofiAPP into the anionic membrane was followed by a rapid
transition from a disordered alpha-helical to a beta-sheet confirmation. Virtually all of the
evidence lends support to the lAPP-membrane interaction hypothesis where, "lAPP showed
significant cytotoxicity of lAPP oligomers, which may permeabilize the P-eel! membrane as
shown by a fluorescence microscopy leakage assay on isolated B-cells in the present study"
(Seeliger eta!. 2012).
lAPP is believed to be a major factor in the transition and pathology from early stages of
type 2 diabetes to the later stages of the disease. A study, Membrane Disruption and Early
Events in the Aggregation of the Diabetes Related Peptide lAPP from a Molecular Prospective
states that,
"Using variants of lAPP that are combinations of toxic or non-toxic and amyloidogenic
or nonamyloidogenic forms, we have shown that formation of amyloid fibers is a
sufficient but not necessaty condition for the disruption of B-cells. Instead, the ability to
induce membrane dismption in model membranes appears to be related to the peptide's
ability to stabilize curvature in the membrane, which in tum is related to the depth of
penetration in the membrane" (Brender, Salamekh, and Ramamoorthy 2011 ).
This is yet another avenue from which to approach the hypothesis ofiAPP-membrane interaction
through the intermediates of lAPP as a possible causal factor in type 2 diabetes. A unique
characteristic of lAPP that is not common to other amylodogenic proteins is its transient
oligomeric state that quickly converts to matme amyloid fibril. Once again, the question is raised
as to the origin of the cytotoxicity, with two proposed hypotheses being endoplasmic reticulum
stress due to the accumulation of misfolded proteins or the formation of reactive oxygen species
due to metal complexation. This study presents two theories for the mechanism of membrane
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disruption with the first being the pore theory previously discussed, in which the oligomers form
pores in the membrane, causing membrane damage. There is support for this theory through
fluorescence microscopy, as well as data collected by adding low concenh·ations of hiAPP to
membranes at low salt concentrations, resulting in a fluctuation occuning in membrane
concentration occuning that is reflective of the opening and closing of individual channels. The
second proposal is that of a "detergent-like mechanism with mosaic-like opening and closing of
transient defects within the membrane that is supported by AFM studies, which show macroscale
defects in the lipid bilayer upon prolonged exposure to hiAPP" (Brender, Salamekh, and
Ramamoorthy 2011). While this was investigated in the trial, it was thought to be less likely
because permeabilization by hiAPP is strongly selective for smaller molecules, which weakens
the case for the large-scale destruction to membranes caused by the proposed detergent-like
effects.
One of the previously mentioned hypotheses proposed for the origin of the
cytotoxicity was through oxygen radicals formed through the synthetic human amylin
peptide, which can generate hydrogen peroxide during incubation in vitro. This study
allowed for the employment of a specific spectrophometric technique to check for
carbonyl group formation, which gives evidence of peptide damage due to the presence
of reactive oxygen species in vitro (Masad et al. 2011). The formation of the hydroxyl
radical, which was formed and proven by spectroscopy is an extremely reactive oxygen
species that results in local oxidation, and, therefore damage, of the peptide. This study
provided clear evidence for oxidative damage to human amylin peptide due to the
detection of carbonyl groups, and
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"The formation of reactive oxygen species in the presence of human amy lin peptide could hold
the key to a better understanding of the damaging consequences of amyloid formation within the
pancreatic islets of patients with type 2 diabetes. Copper- mediated oxidation (and H202
generation) could be an important step in the processes leading to islet

~-cell

degeneration and

progression of type 2 diabetes." (Masad et al. 2011).
While there have been suggestions of lAPP and amyloid being linked to type 2 diabetes
and other amyloidogenic diseases, like Alzheimer's and Parkinson's disease, it was not until
recent times that evidence was presented to prove such a link between amylin and type 2
diabetes. Of particular interest is the fact that while it was originally assumed that the amyloid
fibril deposits are what linked type 2 diabetes to the polypeptide, it is actually caused by its
intermediates. Most evidence points toward an lAPP-membrane cytotoxicity that derives from
the oligomers of lAPP instead of the mature fibril. There are still questions left unanswered
about the origin of the cytotoxicity of the lAPP intermediates, but cases can be made for
endoplasmic reticulum stress due to the build-up of misfolded proteins, as well as for reactive
oxygen radicals that may be formed. There is enough technology to support hypotheses
presented from years ago based on theory, and with continuing technological advances, more
answers will continue to be found. Even with the answers so far discovered, ways to prevent
membrane destruction are cunently in the works as well as using the conelation between
amyloid deposits and type 2 diabetes as a detection tool while the disease is still clinically silent,
but present in the early stages of pathological type 2 pre diabetes. Through science, answers are
being found and the next step is to use such answers for early detection or in order to prevent the
mechanisms that lead to membrane destmction, cytotoxicity, and diseases like type 2 diabetes.

24

Kurkimilis

The Future:

All of the questions that have continued to be answered about the integration of lAPP and
type 2 diabetes have led to possibilities for the possible prevention of the disease. It has been
shown that the major decline of glucose tolerance can be directly attributed to loss of beta cell
function and eventually beta cell death (Kahn, 2003). While beta cell dysfunction is what leads
to hyperglycemia and type 2 diabetes, the formation of amyloid fibrils is also directly increased
with the death of these beta-cells. Therefore, if there is a distinguishable method by which to
reduce the amount of amyloid fibrils that are forming, or more specifically, the oligomer
transition state that leads to the formation of these mature fibrils, it may be possible to improve
glucose tolerance and reduce type 2 diabetes as well.
One possibility in the improvement of glucose tolerance in type 2 diabetics is derived
from the thought of amylin agonists. Since amylin is cosecreted with insulin from the Islet of
Langerhans cells and it inhibits glucagon secretion, it is thought that the replacement of this
peptide hormone could lead to improved glycemic control in some individuals with type 2
diabetes (Schmitz, Brock, & Rung by 2004). The article "Amy lin Agonists: A Novel Approach in
the Treatment of Diabetes", published by Schmitz, Brock, and Rung by, also recognizes the point
that increased amylin presence can also lead to fibril formation, which subsequently leads to
beta-cell death. Due to this large issue in a seemingly easy solution to the issue of
hyperglycemia, a stable analog, prarnlintide, has pharmacokinetic actions and pharmacodynamic
properties of amylin. The stability of this analog offers beneficial uses because it will not
enhance fibrillar formation, but it could improve the glycemic tolerance of individuals. It has
been tested in clinical trials of over 5,000 insulin-treated patients, and 250 patients for greater
than or equal to the time period of two years (2004).
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The amylin analog, pramlintide, differs from amylin in that three proline residues are
substituted at positions 25, 28, and 29 in the amino acid chain, or the primary structme. These
substitutions make pramlintide, "stable, soluble, nonaggregating, and nonadhesive and it has
been shown to exhibit beneficial actions similar to those of native amylin" (Schmitz, Brock, &
Rungby, 2004). The rationale behind replacing amylin with pramlintide in humans is that it
mainly exerts its effects in the postprandial state, or in the fed state. It does so by inhibiting
excessive glucagon secretion and delaying gastric emptying which gives the body a longer time
to process the glucose that is put into the system during a meal. A known effect of the amy lin
analog is it's effect on the satiety factor of obese type 2 diabetics. A 52 week study was
conducted by Schmitz, Brock and Rungby on 656 type 2 diabetics who were treated with insulin.
The subjects in the study were dosed with prarnlintide twice daily in two different dosage groups
through an injection of 90 and 120 micrograms respectively. In the group dosed with 120
micrograms, a 0.62% reduction was seen in the HbA1c levels. Also, in keeping with the positive
effects on satiety in the obese type 2 diabetics, a loss of 1.4 kg was exhibited in the pramlintide
groups versus a gain of 0.7 kg in the placebo group. In the pramlintide group, the daily insulin
dose was significantly reduced as well (Schmitz, Brock, & Rungby 2004).

The benefits

exhibited in several, large-scale phase III trials of over 3,000 type 1 and 2 diabetics using the
synthetic drug pramlintide include decreased HbA1c levels, weight loss, and no increase in
hypoglycemic episodes. In the type 2 diabetics a sustained weight loss over a one year period
was also seen.
Another article released in 2011, "Management of Type 2 Diabetes: New and Future
Developments in Treatment", discusses drugs targeting beta cell dysfunction as a therapeutic
class of prevention. It also discussed pramlintide as a drug that targets the pancreas and acts
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directly or indirectly on beta cells, secreting insulin, C-peptide, and amylin.

The amylin

analogue, pramlintide, was included in a table of available drugs that lower blood glucose, and
was put on the market in 2005. It was cited for its route

through subcutaneous injection

regarding the advantages of weight loss, and its disadvantages of only being used with insulin
(Tahrani et al.).
While there is an amy lin analogue currently on the market, another form of therapeutic means
that is being explored includes its inhibitors.The study conducted by Hebda and Miranker in
2009 states,
"The practical consequences of our cunent biophysical understanding of amyloid toxicity
are twofold. First, therapeutics must prevent accumulation of toxic intermediate
species ... Second, a mechanistically targeted therapeutic need only make modest
alterations to the levels and localization of amyloidogenic species"."
This study presents the point that targeting fibers themselves will not solve the problem, but
could indeed worsen it by causing a build up of amylin intermediates which are the toxic species.
"Suitable targets can include stability of the helical state, helix-helix interactions, proteinmembrane adsorption, and the interconversion of adsorbed states from lateral to
transmembrane orientations ... Stabilization of a helical state or a reduction in helix- helix
interaction energies can be expected to accelerate or alternatively inhibit subsequent
amyloid conversion depending on the balance of energy. For lAPP, the capacity of
hiAPP versus rat lAPP to assemble into a membrane- permeabilizing state rests in part on
the energy of nucleating a membrane-bound helical aggregated state" (Hebda and
Miranker 2009).
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This suggests that a therapeutic strategy should be designed to include molecules that displace
h!APP from the membrane surface, because it may work synergistically with endogenous
insulin.
A large class of inhibitors that is under development focuses on decreasing the amount of
fibril formation, but as previously stated, this is not necessarily beneficial because the
information shows that the known oligomer or other transition states are causing the problem and
not the mature fibril. These inhibitors only decrease the formation of the fibril, not the oligomer,
so they may not be particularly useful according to a review done in 2013 by Ping Cao and
associates that was published on the behalf of Federal of European Biochemical Studies. This
review explored another class of inhibitors that may prove to be more efficient because they
interact with the monomer or very early-formed oligomers in a way that could then prevent the
build up of the toxic species of amylin. An example of such an inhibitor is a biologically active
flavanol in green tea, Epigallocatechin 3-Gallate (EGCG).

It has been shown to bind to

unaggregated polypeptides and has been shown to redirect the formation pathway of amy!in to
instead form nontoxic oligomers instead, meaning that EGCG can inhibit h!APP amyloid
formation, as well as protect against h!APP induced toxicity (Cao eta!. 2013). The mechanisms
for inhibitors, such as EGCG, are not yet known and are still debated, but the action is decisive.
The article states, "One possibility is that the compound interacts with the protein backbone and
also makes non-specific hydrophobic interactions with protein side-chains"(Cao et a!. 2013).
While EGCG seems to be the inhibitor that could be the most effective at the moment, others are
also under investigation;
"Several rationally designed polypeptide inhibitors have been reported to inhibit h!APP
amyloid fonnation and toxicity. For example, certain single proline mutations in the 20-
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29 regwn convert hiAPP into a potent amyloid inhibitor [82,83] and a double Nmethylated variant of hiAPP has been shown to be a very effective inhibitor of amyloid
formation and hiAPP cytotoxicity" (Cao et al, 20 13).
It is thought that the inhibitors mentioned above work by targeting the helical oligomers, but just

as EGCG, no mechanism has yet to be determined. The conclusion of this article was stated
clearly and concisely by explaining that, while these fmdings are groundbreaking and could
provide the world with solutions to type 2 diabetes, there is still research and work to be done.
Some of the questions left to be answered include defming the nature of toxic species and
identifYing the, initiation site or sites of amyloid formation in vivo.
Conclusion:

Type 2 diabetes is a worldwide pandemic that will continue to grow and, through
increased insulin resistance and decreased insulin uptake, high blood glucose or hyperglycemia,
is increasingly hard to combat. Damaged beta cells and eventually beta cell death cause the
pancreas to produce insufficient amounts of insulin, a hormone that helps keep blood glucose in
the homeostatic range by lowering the amolmt in the blood when it is too high. Insulin does so
by aiding in the uptake of blood glucose by cells. Without insulin, this blood glucose is left in the
bloodstream and the cells cannot receive the required energy given to them by glucose, which is
broken down and used by the cell. Beta cell damage and death are large parts of the pathogenesis
in type 2 diabetes, and an investigation into what causes these cells to be damaged and
eventually die is of great interest in hying to combat diabetes. Risk factors that can lead to
diabetes include a genetic predisposition, ethnicity, and obesity, one of the largest risk factors.
There are several modes of tt·eatment curr-ently prescribed for type 2 diabetics, the first of which
includes a lifestyle modification to a healthy diet and regular exercise. It is thought that losing
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weight and regular exercise can improve insulin resistance as well as insulin uptake, but for some
patients these steps will not be enough to conect their hyperglycemia. If lifestyle modification is
not enough, an oral agent is prescribed with one of two major mechanisms of action: either the
pancreas is stimulated to produce more insulin or the liver is regulated to produce less glucose.
The most popular and affordable oral agent on the market cunently is Metformin. If an oral
agent still is not enough to keep a patient's diabetes under control, insulin injections can be an
added to supplement the body with what it can no longer produce on it's own. While all of these
modifications to a person's lifestyle are made in order to combat type 2 diabetes, the biochemical
world has begtm to approach the subject from a molecular basis as a way to prevent the
worsening of diabetes, provide early detection, or possibly one day be able to prevent its onset.
One of the avenues opened through science is that of discerning a strategy to prevent beta
cell damage. Human islet amyloid polypeptide, also known as amylin, is a peptide hormone
cosecreted from the islet cells with insulin. It has been seen in type 2 diabetics that this
polypeptide undergoes a transformation into a mature fibrillar state, causing amyloid depositions
intracellularly in the beta cells. It has now been determined that the mature state of the amyloid
fibrils is not the cause of cell toxicity in the case of type 2 diabetes, but rather its oligomeric
intermediates cause the cytotoxicity to occur at the beta cells. These oligomeric intermediates of
amyloid fibrils have not yet been determined to have one specific mechanism of action for
causing the cytotoxicity, but several theories of cell toxicity have been proposed including beta
cell membrane disruption, endoplasmic reticulum stress, and oxygen radical formation. There is
also a large possibility that a combination of such cytotoxic events caused by the aggregation of
amyloid fibrils is what causes the damage to beta cells. The mechanism of cell toxicity due to
hiAPP fibril deposition is one of the biggest questions left to answer, but even with the research
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done to date, possible solutions to such a molecular level problem have been developed to aid in
solving the large scale problem, type 2 diabetes.
Discoveries made regarding lAPP aggregation into mature fibrils vm cytotoxic,
oligomeric intermediates are on the rise and help us understand a pressing issue considering the
exponential growth of individuals developing type 2 diabetes. Such answers to this problem
include amylin agonists and polypeptide inhibitors. Through therapeutic solutions, such as
pramlintide, a drug put on the market in 2005 to lower glucose by acting as an amy lin agonist, or
Epigallocatechin 3-Gallate (EGCG), produces polypeptide inhibitors that reduce the rate of
fibrillar formation and hiAPP cytotoxicity such as the scientific community is slowly working its
way towards answers. While there are many questions still left to be answered, there has been
substantial progress over the last three decades since the discovery of amylin in 1987. This
progress has led to possible answers not only to what causes amyloid fibril depositions but also
to ways of preventing the healthy polypeptide from aggregating into such a harmful fibril and,
thereby protecting the integrity of the beta cells ofthe pancreas.
Approaching type 2 diabetes from angles other than just those of lifestyle modification
and medication is cmcial in the race to fmd a way to cease the exponential growth of this
debilitating disease. By using knowledge on the scientific, biochemical, and molecular levels the
science community is providing another route of therapy for type 2 diabetes. It is known that
beta cell death is one of the major causes of the significant decrease in the production of insulin
in type 2 diabetics. The scientific community has provided an avenue of research that allows for
the possibility of preserving these beta cells by understanding the mechanisms occurring at a
molecular level involving amylin, which causes their death and subsequent inability to produce
insulin. In a way, using the science behind the disease to prevent it from occurring can be looked
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at as a complex verston of preventative medicine that can aid in halting the seemingly
unstoppable growth of the seventh leading cause of death in the United States, diabetes. Just as
the production of amyloid fibrils increases explosively after a cetiain level of nucleation is
reached, causing increased beta cell death, the level of obesity and unhealthy living has resulted
in an explosion in the number of individuals affected by type 2 diabetes. In much the same way
that amylin agonists or peptide inhibitors can prevent the molecular explosion of fibrils,
continuing research at this molecular level can provide a preventative medicine approach to the
disease that already affects over twentyfive million Americans. The connection between lifestyle
risk factors and type 2 diabetes is as apparent as the connection between the transition of amylin
into deposition of amyloid fibrils and the death of beta cells. In the same way that society intends
to decrease an unhealthy lifestyles to prevent type 2 diabetes, the scientific community looks to
decrease the molecular mechanisms that lead to type 2 diabetes.
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